MedTrace Logo

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

NCT02607553 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-02-24

No results posted yet for this study

Summary

An open-label, single-arm, single-center Phase II study to evaluate the safety and activity of G-202 in patients with clear cell renal cell carcinoma that expresses PSMA

Conditions

Interventions

DRUG

G-202

G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression

Sponsors & Collaborators

  • GenSpera, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Amato, D.O. · University of Texas Health Sciences Center at Houston

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2016-12-31
Completion
2017-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02607553 on ClinicalTrials.gov